Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Phys Lipids ; 234: 105009, 2021 01.
Article in English | MEDLINE | ID: mdl-33189639

ABSTRACT

There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for new and efficacious treatment options for COVID-19. Most COVID-19 deaths result from acute respiratory distress syndrome (ARDS). This virus induces excessive and aberrant inflammation so it is important to control the inflammation as soon as possible. To date, results of numerous studies have been shown that mesenchymal stem cells and their derivatives can suppress inflammation. Exosomes function as intercellular communication vehicles to transfer bioactive molecules (based on their origins), between cells. In this review, the recent exosome-based clinical trials for the treatment of COVID-19 are presented. Potential therapy may include the following items: First, using mesenchymal stem cells secretome. Second, incorporating specific miRNAs and mRNAs into exosomes and last, using exosomes as carriers to deliver drugs.


Subject(s)
COVID-19/therapy , Drug Delivery Systems/methods , Exosomes/transplantation , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells , SARS-CoV-2 , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , COVID-19/immunology , Clinical Trials as Topic , Exosomes/chemistry , Humans , Mesenchymal Stem Cell Transplantation/adverse effects , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Treatment Outcome , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL
...